Allergan is still on the acquisition trail following its failed merger with Pfizer, spending $85 million to acquire privately-held Topokine Therapeutics and its late-stage product for under-eye bags.
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new ...
Allergan will acquire California-based Bonti for an upfront payment of $195 million and additional potential commercial milestone payments, subject to certain adjustments and other customary ...
Allergan Aesthetics To Open Three New U.S. Training Centers To Expand Access To Aesthetics Education
(RTTNews) - Allergan Aesthetics, an AbbVie (ABBV) company, Wednesday announced the expansion of the Allergan Medical Institute or AMI with three new U.S. training centers. AMI offers tailored ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Allergan Aesthetics, an AbbVie company, has unveiled plans to open three new Allergan Medical Institute (AMI) Training ...
New AA (Allergan Aesthetics) Signature Program provides a personalized approach to treatment planning, in combination with Allergan Aesthetics' advanced facial portfolio to address patient needs ...
Merger deal, which values Allergan at around $160 billion, allows Pfizer to locate its tax base in Ireland ...
NORTH CHICAGO, Ill., Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to ...
ALLERGAN Chief Executive, Brent Saunders, has confirmed the company plans to significantly expand its Irish operations with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback